Funding Opportunity RFA-DA-26-001 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.

Notice NOT-AG-24-059 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-24-023 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications for a Sequencing Center to support the new forming population screening network by providing sequencing service for 20,000 study participants, variant calling, annotation and confirmation, interpretation and reporting. This NOFO runs in parallel with companion NOFOs that invite applications for the Clinical Groups (RFA-HG-24-021) and the Coordinating Center (RFA-HG-24-022).

Funding Opportunity RFA-HG-24-021 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications for an implementation and evidence generation pilot program of population screening for common, actionable genomic conditions predominantly in the primary care setting. Specifically, the multi-site program will: 1) select, implement, and evaluate screening for 4-8 genomic conditions in diverse populations and primary care settings; 2) use established strategies for meaningful community engagement in all phases of design, conduct, and evaluation; and 3) develop effective strategies for connecting patients found to have genomic risk variants to follow-up care. This NOFO runs in parallel with companion NOFOs that invite applications for the Coordinating Center (RFA-HG-24-022) and the Sequencing Center (RFA-HG-24-023).

Funding Opportunity RFA-HG-24-022 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications for a Coordinating Center to participate in forming a network of population screening in primary care to identify and improve approaches for clinical implementation of genomic screening in primary care. This NOFO runs in parallel with companion NOFOs that invite applications for the Clinical Groups (RFA-HG-24-021) and the Sequencing Center (RFA-HG-24-023).

Funding Opportunity RFA-DA-26-002 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses.

The University of Texas at Arlington: Posting Number: F00546P Position Title: Multiple Open Rank Faculty Positions - Precision Health and Informatics Cluster Department: Provost Office... Arlington, Texas

Grossmont-Cuyamaca Community College District: Biology Faculty (Cellular, Molecular, And Evolutionary Biology) - Tenure Track R-01765 San Diego County - Grossmont College Transforming lives thro... El Cajon, California

Notice NOT-AT-24-041 from the NIH Guide for Grants and Contracts

Notice NOT-HL-24-018 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-037 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders include; Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).

Notice NOT-GM-24-044 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DE-25-004 from the NIH Guide for Grants and Contracts. The objective of this initiative is to support highly integrated research teams to address challenging questions with the potential to significantly advance dental, oral and craniofacial (DOC) fields of research. Each project should have a unified and well-defined scientific goal within the NIDCR mission that requires a team with diverse perspectives and expertise in a variety of intellectual or technical areas and is beyond the experience and capabilities of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions.

Funding Opportunity PAR-24-269 from the NIH Guide for Grants and Contracts. The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorders (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of genomic variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include genomics analysis at the circuit level and the application of neuroscience to genomics studies. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.

Funding Opportunity RFA-CA-24-028 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enable the provision of support for AIDS Malignancy Consortium (AMC). AMC is a major infrastructure intended to stimulate cooperative research efforts in the following areas: Design, development, and evaluation of clinical interventions for the prevention and treatment of HIV-associated malignancies; Development of more effective therapeutics and management strategies for HIV-associated malignancies; Investigation of the biology of HIV malignancies within the context of clinical trials; Management of issues of international importance in HIV associated-malignancies; and Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource (ACSR) for ongoing or future investigations. The AMC must consist of the following functional units: a Coordination Center; Clinical Trial Sites; Network Laboratories; and a Statistical Center. The AMC team must have scientific disease-oriented Working Groups to study Kaposi Sarcoma, Hematologic Malignancies , Human papilloma virus-associated cancers, and Solid Tumors in people with HIV. The Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to subjects of all racial/ethnic groups.

Notice NOT-OD-24-164 from the NIH Guide for Grants and Contracts

Albert Einstein College of Medicine: We are looking for a motivated and experienced Bioinformatics Analyst to join Dr. Robert Burk's research group. This role is critical for supportin... Bronx, New York

£37,890 - £41,438 per annum: Rothamsted Research: Are you a knowledgeable statistician with an appetite for tackling the real-world challenges of modern sustainable... AL5 2JQ, Harpenden, Hertfordshire but with travel to Devon

Funding Opportunity RFA-DK-25-016 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs. The NOFO is open to new applications, not renewals. Previously funded PKD Centers may apply as new centers.

Funding Opportunity RFA-DK-25-015 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) requests applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers (RTCC). The CCS is expected to work collaboratively with four RTCCs as part of the PKD Research Consortium and serve as a national resource for the larger research community. The CCS will provide central administrative and communications support for the Consortium. All activities within the Consortium are expected to address the overall goal of improving our understanding of the pathogenesis, progression, prevention and clinical management of PKD through enhanced sharing of resources and establishment of a robust research community. This NOFO is a companion announcement to RFA-DK-25-016:Polycystic Kidney Disease Research and Translation Core Centers (U54).